The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Virtual drug discovery and development for neglected diseases through public–private partnerships
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Medical need, scientific opportunity and the drive for antimalarial drugs
Ridley, R. G. (2002) · Nature · doi:10.1038/415686a · Cited by 789
Self-citationOral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
A Comparison of the J-lntegral and CTOD Parameters for Short Crack Specimen Testing
Sorem, W., Dodds, R., & Rolfe, S. (1991) · Elastic-Plastic Fracture Test Methods: The User's Experience (Second Volume) · doi:10.1520/stp16845s · Cited by 392
Profiling drug-like properties in discovery research
Di, L., & Kerns, E. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00055-3 · Cited by 278
Drugs for neglected diseases: a failure of the market and a public health failure?
Trouiller, P., Torreele, E., Olliaro, P., White, N. J., Foster, S. D., Wirth, D. F., & Pécoul, B. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00803.x · Cited by 229
Widdus, R. (2017) · Global Health · doi:10.4324/9781315254227-32 · Cited by 225
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Harnessing the Power of the Genome in the Search for New Antibiotics
Rosamond, J., & Allsop, A. (2000) · Science · doi:10.1126/science.287.5460.1973 · Cited by 186
Cysteine Proteases of Malaria Parasites: Targets for Chemotherapy
Rosenthal, P., Sijwali, P., Singh, A., & Shenai, B. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394197 · Cited by 185
Richards, F. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90780-4 · Cited by 176
Antimalarial Chemotherapy. Mechanisms of Action, Resistance and New Directions in Drug Discovery
(2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg183 · Cited by 157
Two decades of orphan product development
Haffner, M. E., Whitley, J., & Moses, M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd919 · Cited by 137
Strategic emphases for tropical diseases research: a TDR perspective
Remme, J. H. F., Blas, E., Chitsulo, L., Desjeux, P. M. P., Engers, H. D., Kanyok, T. P., Kengeya‐Kayondo, J. F., Kioy, D. W., Kumaraswami, V., Lazdins, J. K., et al. (2002) · Trends in Parasitology · doi:10.1016/s1471-4922(02)02387-5 · Cited by 102
Self-citationDrug metabolism and pharmacokinetics in drug discovery.
Roberts, S. A. (2003) · PubMed · Cited by 95
The development of Lapdap, an affordable new treatment for malaria
Lang, T. A., & Greenwood, B. M. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00547-4 · Cited by 74
Initial lessons from public-private partnerships in drug and vaccine development.
Wheeler, C. J., & Berkley, S. (2001) · PubMed · Cited by 68
Chlorproguanil‐dapsone (LAPDAP) for uncomplicated falciparum malaria
Winstanley, P. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00751.x · Cited by 55
Plasmodium:Drug Discovery and Development—An Industrial Perspective
Ridley, R. G. (1997) · Experimental Parasitology · doi:10.1006/expr.1997.4230 · Cited by 42
Self-citationThe further evolution of biotech
Nagle, T., Berg, C., Nassr, R., & Pang, K. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd989 · Cited by 38
The Role of Genomics in Antibacterial Target Discovery
Buysse, J. M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013371699 · Cited by 32
Genomics: from novel genes to new therapeutics in parasitology
Gutierrez, J. A. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00005-9 · Cited by 23
Product R&D for neglected diseases
Ridley, R. G. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor858 · Cited by 20
Self-citationGenomes and Genome Projects of Protozoan Parasites
Ersfeld, K. (2003) · Current Issues in Molecular Biology · doi:10.21775/cimb.005.061 · Cited by 15
Cited by
Antimalarial drug discovery: efficacy models for compound screening
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R., & Nwaka, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1416 · Cited by 861
Self-citationIdentification of an antimalarial synthetic trioxolane drug development candidate
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., et al. (2004) · Nature · doi:10.1038/nature02779 · Cited by 622
Opportunities and Challenges in Antiparasitic Drug Discovery
Pink, R., Hudson, A., Mouriès, M.-A., & Bendig, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1824 · Cited by 545
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Self-citationNathan, C. (2004) · Nature · doi:10.1038/431899a · Cited by 410
Metadata
- Authors
- Nwaka, S., & Ridley, R. G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-11
- Volume
- 2
- Issue
- 11
- Pages
- 919-928
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2767249111
- Cited by
- 260
- References
- 30
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.